// App-Quantinova.ai

DOP067 : Treatment discontinuation, flares and hospitalisations among biologic-naïve patients with IBD over the first year of treatment: a comparative effectiveness study of vedolizumab vs. infliximab

Researchers

Presenter

  • M Raluy-Callado

Principal Investigators

  • A Berger

  • J M Khalid

  • H Patel

Medical Centers

  • Evidera, Real World Evidence, London, United Kingdom

  • Evidera, Real World Evidence, Waltham, MA, USA

  • Takeda Development Centre Europe Ltd., Evidence and Value Generation, London, UK

Locations

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Entyvio

  • Infliximab

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved